Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin and Insulin in Hospitalized COVID-19 Patients
NCT04542213Phase 3Completed
- Sponsor
- Hospital Regional de Alta Especialidad del Bajío
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linagliptin in coronavirus disease 2019 (COVID-19) and hyperglycemia (2 arms), sponsored by Hospital Regional de Alta Especialidad del Bajío. Primary endpoints: Glucose levels and Number of patients who achieve metabolic control. Started Aug 2020; status: completed.
02
Drugs
linagliptin
03
Conditions
coronavirus disease 2019 (COVID-19)hyperglycemia
Beyond the preview
Go deeper on NCT04542213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542213.